{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T23:13:50Z","timestamp":1790723630417,"version":"4.1.0"},"reference-count":18,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2015,6,1]],"date-time":"2015-06-01T00:00:00Z","timestamp":1433116800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,6,1]],"date-time":"2015-06-01T00:00:00Z","timestamp":1433116800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,11,9]],"date-time":"2022-11-09T00:00:00Z","timestamp":1667952000000},"content-version":"vor","delay-in-days":2718,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["jthjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Thrombosis and Haemostasis"],"published-print":{"date-parts":[[2015,6]]},"DOI":"10.1111\/jth.12929","type":"journal-article","created":{"date-parts":[[2015,6,21]],"date-time":"2015-06-21T08:15:36Z","timestamp":1434874536000},"page":"S176-S179","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":78,"special_numbering":"S1","title":["Half\u2010life extended factor VIII for the treatment of hemophilia A"],"prefix":"10.1016","volume":"13","author":[{"given":"A.","family":"Tiede","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1111\/jth.12929_bb0010","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1056\/NEJMoa067659","article-title":"Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia","volume":"357","author":"Manco\u2010Johnson","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1111\/jth.12929_bb0015","doi-asserted-by":"crossref","first-page":"4648","DOI":"10.1182\/blood-2006-11-056291","article-title":"Treatment\u2010related risk factors of inhibitor development in previously untreated patients with hemophilia A: the CANAL cohort study","volume":"109","author":"Gouw","year":"2007","journal-title":"Blood"},{"key":"10.1111\/jth.12929_bb0020","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1007\/s00228-009-0676-x","article-title":"Pharmacokinetics and dose requirements of factor VIII over the age range 3\u201074\u00a0years: a population analysis based on 50 patients with long\u2010term prophylactic treatment for haemophilia A","volume":"65","author":"Bjorkman","year":"2009","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1111\/jth.12929_bb0025","doi-asserted-by":"crossref","first-page":"3031","DOI":"10.1182\/blood-2011-09-382846","article-title":"Safety and prolonged activity of recombinant factor VIII Fc fusion protein in hemophilia A patients","volume":"119","author":"Powell","year":"2012","journal-title":"Blood"},{"key":"10.1111\/jth.12929_bb0030","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1182\/blood-2013-10-529974","article-title":"Phase 3 study of recombinant factor VIII Fc fusion protein in severe hemophilia A","volume":"123","author":"Mahlangu","year":"2014","journal-title":"Blood"},{"key":"10.1111\/jth.12929_bb0035","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1182\/blood-2012-01-407494","article-title":"A novel B\u2010domain O\u2010glycoPEGylated FVIII (N8\u2010GP) demonstrates full efficacy and prolonged effect in hemophilic mice models","volume":"121","author":"Stennicke","year":"2013","journal-title":"Blood"},{"key":"10.1111\/jth.12929_bb0040","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1111\/jth.12161","article-title":"Enhancing the pharmacokinetic properties of recombinant factor VIII: first\u2010in\u2010human trial of glycoPEGylated recombinant factor VIII in patients with hemophilia A","volume":"11","author":"Tiede","year":"2013","journal-title":"J Thromb Haemost"},{"key":"10.1111\/jth.12929_bb0045","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1182\/blood-2009-11-254755","article-title":"Rational design of a fully active, long\u2010acting PEGylated factor VIII for hemophilia A treatment","volume":"116","author":"Mei","year":"2010","journal-title":"Blood"},{"key":"10.1111\/jth.12929_bb0050","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1111\/hae.12374","article-title":"Evaluation of the activated partial thromboplastin time assay for clinical monitoring of PEGylated recombinant factor VIII (BAY 94\u20109027) for haemophilia A","volume":"20","author":"Gu","year":"2014","journal-title":"Haemophilia"},{"key":"10.1111\/jth.12929_bb0055","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1111\/jth.12506","article-title":"Phase I study of BAY 94\u20109027, a PEGylated B\u2010domain\u2010deleted recombinant factor VIII with an extended half\u2010life, in subjects with hemophilia A","volume":"12","author":"Coyle","year":"2014","journal-title":"J Thromb Haemost"},{"issue":"Suppl. 3","key":"10.1111\/jth.12929_bb0060","first-page":"20","article-title":"Safety and efficacy of prophylaxis and on\u2010demand treatment with BAY 94\u20109027: results of a phase 2\/3, multicenter, partially randomized, open\u2010label trial (PROTECT VIII)","volume":"20","author":"Reding","year":"2014","journal-title":"Haemophilia"},{"issue":"Suppl. 1","key":"10.1111\/jth.12929_bb0065","first-page":"S29","article-title":"BAX, 855, a PEGylated rFVIII product with prolonged half\u2010life. Development, functional and structural characterisation","volume":"32","author":"Turecek","year":"2012","journal-title":"Hamostaseologie"},{"key":"10.1111\/jth.12929_bb0070","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1111\/hae.12532","article-title":"The biological efficacy profile of BAX 855, a PEGylated recombinant factor VIII molecule","volume":"21","author":"Valentino","year":"2015","journal-title":"Haemophilia"},{"key":"10.1111\/jth.12929_bb0075","unstructured":"Bevan DH, Conlan M, Mant T, Lissitchkov T, Kazmi R, Chowdary P, Langer F, Shima M, Fukutake K, Singer J, Grigorian A, Ewenstein B, Wong WY. A phase 1 study of safety and pharmacokinetics (PK) of BAX 855, a longer acting PEGylated full\u2010length recombinant factor VIII (PEG\u2010rFVIII), in patients with severe haemophilia A. EAHAD 2013 poster presentation."},{"issue":"Suppl. 1","key":"10.1111\/jth.12929_bb0080","doi-asserted-by":"crossref","first-page":"S9","DOI":"10.1016\/S0049-3848(12)70003-8","article-title":"Pioneering designs for recombinant coagulation factors","volume":"128","author":"Schulte","year":"2011","journal-title":"Thromb Res"},{"key":"10.1111\/jth.12929_bb0085","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.thromres.2013.06.017","article-title":"Preclinical efficacy and safety of rVIII\u2010SingleChain (CSL627), a novel recombinant single\u2010chain factor VIII","volume":"132","author":"Zollner","year":"2013","journal-title":"Thromb Res"},{"key":"10.1111\/jth.12929_bb0090","article-title":"Population pharmacokinetic modeling and simulation of recombinant single\u2010chain factor VIII (rVIII\u2010SingleChain) in patients with hemophilia A","author":"Zhang","year":"2014","journal-title":"Blood"},{"key":"10.1111\/jth.12929_bb0095","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1111\/j.1538-7836.2008.03270.x","article-title":"Break\u2010through bleeding in relation to predicted factor VIII levels in patients receiving prophylactic treatment for severe hemophilia A","volume":"7","author":"Collins","year":"2009","journal-title":"J Thromb Haemost"}],"container-title":["Journal of Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fjth.12929","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fjth.12929","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783622042258?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783622042258?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/jth.12929\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T03:12:11Z","timestamp":1761534731000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1538783622042258"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,6]]},"references-count":18,"alternative-id":["S1538783622042258"],"URL":"https:\/\/doi.org\/10.1111\/jth.12929","relation":{},"ISSN":["1538-7836"],"issn-type":[{"value":"1538-7836","type":"print"}],"subject":[],"published":{"date-parts":[[2015,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Half\u2010life extended factor VIII for the treatment of hemophilia A","name":"articletitle","label":"Article Title"},{"value":"Journal of Thrombosis and Haemostasis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1111\/jth.12929","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 International Society on Thrombosis and Haemostasis. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}